Actavis seeks FDA ANDA approval for generic Zubsolv.

Actavis seeks FDA ANDA approval for generic Zubsolv, confirms patent challenge Actavis plc today confirmed that it has filed an Abbreviated New Medication Software with the U .S. Food and Drug Administration seeking authorization to advertise Buprenorphine Hydrochloride and Naloxone Hydrochloride Dihydrate Sublingual Tablets, Eq, 1.4 mg/0.36 mg and 5.7 mg/1.4 mg Base. Related StoriesMylan sued regarding the ANDA submitting for generic version of ZytigaMylan announces U.S. Launch of generic Fusilev for InjectionImmune submits Bertilimumab IND program to FDA for treatment of Bullous PemphigoidOrexo Abdominal and Orexo US, Inc. On June 26 filed suit against Actavis, 2014, in the U.S.

People should be galvanized to work to avoid the tragedy, not only wait around for it to occur’ . This article was reprinted from with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an unbiased news service editorially, is a scheduled plan of the Kaiser Family Foundation, a nonpartisan healthcare policy research company unaffiliated with Kaiser Permanente.. Work now ‘to prevent tragedy’ in Africa’s Sahel food security crisis ‘The world appears reluctant to open its wallets to relief organizations dedicated to keeping the lives of Africa’s kids until it’s official.